Pharmion, MethylGene begin phase 2 trial of MGCD0103 in lymphoma

By Lisa Kerner

Charlotte, N.C., Sept. 15 - Pharmion Corp. and MethylGene, Inc. enrolled the first patient in a phase 2 clinical trial (Trial 008) of MGCD0103, a histone deacetylase inhibitor, in patients with relapsed or refractory B-cell lymphomas.

The study will determine the effectiveness of MGCD0103 and its safety profile as well as assess biomarkers and predictive markers for MGCD0103.

Up to 82 patients will be enrolled in the open-label, single-agent trial at several cancer centers in North America.

MGCD0103 will be given orally, three times per week at a flat dose of 110 mg for up to 24 months.

Pharmion is a Boulder, Colo., biopharmaceutical company.

MethylGene is a biopharmaceutical company located in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.